Mona Ashiya
QuietNamed in filings at Orbimed Private InvestmentsOn the current fund
- Board seats filed
- 2
- Named on a board
all filings on record
Named in filings at Orbimed Private InvestmentsOn the current fund
all filings on record
last 24 months
from a verified or cited source
| VANQUA BIO | Biotech & pharma | September 2019 | 270 Healthcare Growth, Caduceus Capital, Orbimed Asia Partners, Orbimed Genesis, Orbimed Global Healthcare, Orbimed Israel Partners, Orbimed New Horizons, Orbimed Partners |
| Prevail Therapeutics | Biotech & pharma | March 2018 | Caduceus Capital, Orbimed Asia Partners, Orbimed Genesis, Orbimed Global Healthcare, Orbimed Israel Partners, Orbimed New Horizons, Orbimed Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Too few filings to infer a focus. 2 of 2 filed seats classified so far.